Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NeOnc Technologies Holdings, Inc. ( (NTHI) ) just unveiled an announcement.
NeOnc Technologies reported Q4 and full-year 2025 results on April 1, 2026, highlighting completion of the Phase 1 trial for NEO212 with a recommended Phase 2 dose of 610 mg and early signs of anti-tumor activity in recurrent glioblastoma and brain metastasis patients. The company also fully enrolled its NEO100 Phase 2a trial in recurrent IDH1-mutant high-grade glioma and released updated Phase 1/2a and compassionate-use data showing higher radiographic remission and progression-free survival rates versus historical benchmarks, with no significant toxicity.
Operationally, NeOnc advanced its Middle East expansion via its NuroMENA subsidiary in the UAE, secured a PIPE financing anchored by a $10 million commitment from Cinctive Capital, and strengthened leadership by appointing a new CEO, CAO, and prominent neuro-oncologists to its scientific advisory board. Financially, Q4 2025 general and administrative and R&D expenses rose to $4.8 million and $3.6 million respectively, contributing to a widened net loss of $62.1 million, underscoring both the accelerated investment in clinical programs and the near-term cost burden on shareholders as the company pursues pivotal studies and regional partnerships.
The most recent analyst rating on (NTHI) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on NeOnc Technologies Holdings, Inc. stock, see the NTHI Stock Forecast page.
Spark’s Take on NTHI Stock
According to Spark, TipRanks’ AI Analyst, NTHI is a Neutral.
The score is held back primarily by weak financial fundamentals (large losses, negative equity, and heavier cash burn), partially offset by constructive technicals with the stock trading above key moving averages and moderate momentum. Valuation is also a drag due to the negative P/E and lack of dividend yield.
To see Spark’s full report on NTHI stock, click here.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing central nervous system cancer therapeutics that can overcome the blood-brain barrier. Its NEO drug development platform has yielded patented candidates NEO100 and NEO212, which are in Phase II trials for malignant gliomas under FDA Fast-Track and IND status, supported by an exclusive worldwide patent license from the University of Southern California.
The company’s proprietary chemotherapy agents and delivery methods target various oncological and neurological conditions, with patent protections extending to 2038. NeOnc’s strategy centers on advancing first-in-class CNS-penetrant therapies and leveraging its pipeline and partnerships to commercialize treatments for high-grade gliomas and other brain cancers.
Average Trading Volume: 52,757
Technical Sentiment Signal: Strong Sell
Current Market Cap: $141.6M
Learn more about NTHI stock on TipRanks’ Stock Analysis page.